US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

165.56

-0.1000-0.06%

Volume:5.06M

Turnover:839.38M

Market Cap:42.99B

PE:-11.65

High:167.10

Open:166.83

Low:165.11

Close:165.66

52wk High:176.60

52wk Low:133.73

Shares:259.67M

Float Shares:259.67M

Volume Ratio:0.69

T/O Rate:1.95%

Dividend:2.53

Dividend Rate:1.53%

EPS(TTM):-14.2170

EPS(LYR):-14.2170

ROE:-9.22%

ROA:1.03%

PB:1.25

PE(LYR):-11.65

Loading ...

Overview Company News Filings

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)

Spire Healthcare grants Toscafund brief extension on potential 250p-per-share bid

Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints

MT Newswires Live

AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study

J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals

Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26

THOMSON REUTERS

Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections

THOMSON REUTERS

Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial

THOMSON REUTERS

Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

THOMSON REUTERS

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS

Press Release: PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/XLV/news?page=15"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLV\",,,,,undefined,":{"symbol":"XLV","market":"US","secType":"STK","nameCN":"Health Care Select Sector SPDR Fund","latestPrice":165.56,"timestamp":1789155444542,"preClose":165.66,"halted":0,"volume":5063736,"delay":0,"changeRate":-0.0006036460219726809,"floatShares":259665324,"shares":259665324,"eps":-14.217021,"marketStatus":"Trading","change":-0.1,"latestTime":"09-11 15:37:25 EDT","open":166.83,"high":167.1,"low":165.11,"amount":839381944.15032,"amplitude":0.012013,"askPrice":165.57,"askSize":180,"bidPrice":165.55,"bidSize":536,"shortable":3,"etf":1,"ttmEps":-14.217021,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":165.66,"sharesOutstanding":265215324,"nav":166.521741,"aum":43214943490.73,"dividendRate":0.015309,"bidAskSpread":0.000112,"preHourTrading":{"tag":"盘前","latestPrice":167.05,"preClose":165.66,"latestTime":"09:25 EDT","volume":5188,"amount":863934.91656,"timestamp":1789133148613,"change":1.39,"changeRate":0.008391,"amplitude":0.008753},"postHourTrading":{"tag":"盘后","latestPrice":165.7,"preClose":165.66,"latestTime":"19:59 EDT","volume":325477,"amount":53922798.3581,"timestamp":1789084759969,"change":0.04,"changeRate":0.000241,"amplitude":0.004407},"volumeRatio":0.687146,"optionData":{"bulkOrders":[{"symbol":"XLV","call":false,"expireDate":1805428800000,"strike":"110.0","timestamp":1789142194464,"price":0.1,"volume":1399,"amount":13990,"type":"-"}]},"impliedVol":0.1686,"impliedVolPercentile":0.3745},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLV\",,,,,undefined,":{"symbol":"XLV","floatShares":259665324,"roa":"1.03%","roe":"-9.22%","lyrEps":-14.217021,"volumeRatio":0.687146,"shares":259665324,"dividePrice":2.5346,"high":167.1,"amplitude":0.012013,"preClose":165.66,"low":165.11,"week52Low":133.725,"pbRate":"1.25","psRate":"65.27","week52High":176.595,"institutionHeld":0.7846,"latestPrice":165.56,"committee":0.497207,"eps":-14.217021,"divideRate":0.015309,"volume":5063736,"delay":0,"ttmEps":-14.217021,"open":166.83,"prevYearClose":154.8,"prevWeekClose":171.45,"prevMonthClose":170.54,"prevQuarterClose":158.66,"fiveDayClose":173.26,"twentyDayClose":168.38,"sixtyDayClose":152.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLV\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"XLV","amount":0.656252,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-24","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-24"},{"date":"2026-03-23","symbol":"XLV","amount":0.59468,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-25","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-25"},{"date":"2025-12-22","symbol":"XLV","amount":0.656822,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-24"},{"date":"2025-09-22","symbol":"XLV","amount":0.624868,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-24","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-24"},{"date":"2025-06-23","symbol":"XLV","amount":0.630382,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"健康照护类股ETF-SPDR","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-25","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLV\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-26","value":0.278502,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-27","value":0.305416,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-27","value":0.273839,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-26","value":0.307823,"currency":"USD"},{"executeDate":"2017-09-15","recordDate":"2017-09-18","paymentDate":"2017-09-25","value":0.304755,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLV\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLV\",pageSize:20,pageCount:15,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664031788","title":"Summit Therapeutics Says it is Beating Merck with Its Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664031788","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664031788?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:00","pubTimestamp":1788451200,"startTime":"0","endTime":"0","summary":"Shares of the drug developer Summit Therapeutics were up more than 12% Thursday morning on news that its drug is performing well in a Chinese lung cancer study.Summit stock jumped to $16.46 after the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250843.SGD","LU0432979614.USD","VHT","IE00B1BXHZ80.USD","LU0106261372.USD","LU0985320562.USD","LU0058720904.USD","HRTS","PAWZ","BK4585","LU0203345920.USD","IE00BLSP4452.SGD","LU1023059063.AUD","BK4534","LU0238689110.USD","LU2360032135.SGD","LU0130102774.USD","LU1116320901.HKD","IE00BJT1NW94.SGD","SG9999002224.SGD","LU2324357040.USD","LU1989771016.USD","LU0965508806.USD","SG9999001176.USD","LU2125909247.SGD","LU2433249047.HKD","IE00B4R5TH58.HKD","LU1032466523.USD","SG9999015341.SGD","LU1162221912.USD","LU1941712348.USD","LU1093756325.SGD","LU1035773651.USD","LU0122379950.USD","LU1917777945.USD","LU0006306889.USD","LU1929549753.HKD","BK4533","LU2361044949.HKD","LU2468319806.SGD","BK4139","LU1699723380.USD","IHE","LU1116320737.USD","LU0208291251.USD","LU1934455277.USD","LU0648001328.SGD","LU0868494617.USD","SG9999001176.SGD","LU1983299246.USD","FTXH","LU1057294990.SGD","LU2491049909.HKD","LU0965509101.SGD","SGXZ57979304.SGD","LU1430594728.SGD","LU0265550359.USD","LU1037948897.HKD","SG9999013999.USD","IXJ","LU0266013472.USD","SG9999001440.SGD","LU1037948541.HKD","LU2461242641.AUD","LU2491050154.USD","LU1066053197.SGD","LU0689626769.HKD","LU1989772840.SGD","SG9999014567.USD","LU1989772923.USD","LU0868494708.USD","SG9999014542.SGD","LU1066051225.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU2125909593.SGD","IE00BFTCPJ56.SGD","LU0980610538.SGD","RXL","LU2089984988.USD","XLV","MRK","LU2491050071.SGD","LU2357627491.SGD","LU1941712264.USD","LU2106854487.HKD","LU1093756168.USD","LU1571399168.USD","LU1201861249.SGD","LU0289739699.SGD","LU2125154935.USD","JDOC","LU1585245621.USD","IE0009355771.USD","GDOC","BK4588","IE000M9KFDE8.USD","LU0203347892.USD","LU0211331839.USD","LU1934455863.HKD","BK4550","LU0823416689.USD","LU0861579265.USD","LU0965509283.SGD","SMMT","LU0965509010.AUD","LU0130517989.USD","LU2488822045.USD","IE00BSNM7G36.USD","PPH","LU2361045086.USD","LU0477156953.USD","LU0320765646.SGD","IE00BN8TJ469.HKD","LU1923622614.USD","IE0002141913.USD","LU1066051498.USD","IE00B2B36J28.USD","LU0070302665.USD","LU1974910355.USD","LU1061106388.HKD","SG9999014559.SGD","IE00BJJMRZ35.SGD","LU1069347547.HKD","LU0234572021.USD","LU2023250504.SGD","LU0124676726.USD","BK4559","LU2125154778.USD","BMED","LU2361044865.SGD","FHLC","SG9999014575.USD","LU1291159041.SGD","BK4007","SG9999015358.SGD","BK4516","IYH","TRUH","LU0098860793.USD","SG9999002232.USD","LU1934455194.USD","LU0265550946.USD","LU1066051811.HKD","LU0859254822.USD","LU0942090050.USD","LU2112291526.USD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803903","title":"Analysts’ Top Healthcare Picks: Align Tech (ALGN), Eledon Pharmaceuticals (ELDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803903?lang=en_us&edition=fundamental","pubTime":"2026-09-03 23:50","pubTimestamp":1788450609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Align Tech (ALGN) and Eledon Pharmaceuticals (ELDN) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-align-tech-algn-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-align-tech-algn-eledon-pharmaceuticals-eldn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4504","BK4588","BK4534","ALGN","LABU","BK4139","HCSG","BK4585","LU1917777945.USD","GLAM","LU0029874061.USD","LU2106854487.HKD","LU2023250504.SGD","XBI","LU0128526141.USD","BK4198","LU2023250843.SGD","ELDN","BK4137","BK4581","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080334","title":"Spire Healthcare grants Toscafund brief extension on potential 250p-per-share bid","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080334","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664080334?lang=en_us&edition=fundamental","pubTime":"2026-09-03 23:32","pubTimestamp":1788449563,"startTime":"0","endTime":"0","summary":"Spire Healthcare ( ($GB:SPI) ) has provided an announcement. Spire Healthcare has disclosed that Toscafund Asset Management, its second-largest sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spire-healthcare-grants-toscafund-brief-extension-on-potential-250p-per-share-bid?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spire-healthcare-grants-toscafund-brief-extension-on-potential-250p-per-share-bid?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4585","HCSG","BK4581","XLV","BK4588","LU0029874061.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808827","title":"Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808827?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:30","pubTimestamp":1788445821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE), Alumis Inc. (ALMS) and Omnicell (OMC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-uniqure-qure-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-uniqure-qure-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","QURE","BK4007","BK4139","LU0128526141.USD","BK4137","BK4581","LU0029874061.USD","LU0320765992.SGD","ALMS","BK4588","LABU","XLV","HCSG","BK4585","XBI","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664704888","title":"Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664704888","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664704888?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:10","pubTimestamp":1788444623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Teva Pharmaceutical ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-teva-pharmaceutical-teva-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LABU","CANC","IE0002141913.USD","IE00B2B36J28.USD","BK4581","IE00B4R5TH58.HKD","LU0109394709.USD","LU0889565916.HKD","BK4596","LU0128526141.USD","RVMD","TEVA","BK4139","LU2324357040.USD","BK4557","IDNA","IE0009354923.USD","BK4588","PTH","HCSG","IE00BJT1NW94.SGD","BK4559","BK4566","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0320765992.SGD","BK4137","BK4585","XBI","XLV","LU0029874061.USD","BBH","LU1983299246.USD","IE00BFTCPJ56.SGD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664870565","title":"AbbVie's Phase 3 Study of Etentamig in Multiple Myeloma Meets Dual Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870565","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664870565?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:07","pubTimestamp":1788444473,"startTime":"0","endTime":"0","summary":"AbbVie's (ABBV) phase 3 study of etentamig in patients with triple-class exposed relapsed/refractory multiple myeloma met its dual primary endpoints of objective response rate and progression-free sur","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2089984988.USD","LU0820561909.HKD","IE0004445239.USD","PPH","IE00BJT1NW94.SGD","RXL","SG9999015952.SGD","FHLC","LU1057294990.SGD","LU0661504455.SGD","TRUH","LU2468319806.SGD","LU1923622614.USD","LU2237443549.SGD","IE00BVYPNW00.USD","LU0320765646.SGD","FTXH","GLAM","LU0289739699.SGD","LU1670628061.USD","IE000SO60NU8.SGD","SG9999001440.SGD","PJP","MEDX","SG9999003800.SGD","LU2357627491.SGD","VHT","LU0965509010.AUD","AGNG","IYH","LU0256863902.USD","LU0456855351.SGD","LU1718418525.SGD","LU0965509283.SGD","IXJ","BK4581","LU0289739343.SGD","ABBV","LU1267930490.SGD","LU1732799900.SGD","IE00BGHQF631.EUR","IE00BBT3K403.USD","JDOC","XLV","LU2129689514.USD","IE0009355771.USD","SG9999015986.USD","LU2237443465.HKD","LU2433249047.HKD","IE000WAW04H5.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587722","title":"AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587722","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587722?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:42","pubTimestamp":1788442920,"startTime":"0","endTime":"0","summary":"AbbVie said a drug to treat blood cancer met its dual primary endpoints in a phase 3 study.The company said etentamig demonstrated a significantly higher objective response rate and improvements in pr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VHT","LU0289961442.SGD","IE00B42XCP33.USD","TRUH","PPH","IE00BBT3K403.USD","SG9999001440.SGD","IXJ","LU0170899867.USD","LU0211328371.USD","ABBV","AGNG","IE000BZT7R73.USD","IE00BVYPNV92.GBP","LU1291159041.SGD","PJP","JDOC","LU1003077747.HKD","IE000F7OJYX1.SGD","FTXH","LU0203347892.USD","LU0859254822.USD","LU1093756325.SGD","LU1732799900.SGD","LU0256863902.USD","RXL","FHLC","LU0868494617.USD","IE00BLSP4452.SGD","IE0000B7K699.USD","LU0472753341.HKD","LU0124676726.USD","BK4585","LU2237443978.SGD","LU1244550221.USD","LU2112291526.USD","XLV","LU1989771016.USD","LU2129689431.USD","LU0861579265.USD","IE00BDGV0183.EUR","LU0823416689.USD","GLAM","IYH","MEDX","LU0868494708.USD","LU1551013342.USD","IE00B19Z3B42.SGD","LU2089283258.USD","LU0098860793.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877405","title":"J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877405","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877405?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:25","pubTimestamp":1788441955,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/j-p-morgans-salveen-richter-reiterates-buy-on-teva-citing-tev-408-phase-2a-success-and-pipeline-in-a-product-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/j-p-morgans-salveen-richter-reiterates-buy-on-teva-citing-tev-408-phase-2a-success-and-pipeline-in-a-product-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4504","LU1720051017.SGD","LU1894683264.USD","LU0912757837.SGD","LU1144417596.USD","LABU","LU2487616109.SGD","LU0528227936.USD","BK4557","IE0004091025.USD","LU1988902786.USD","LU2237443895.HKD","LU0971096721.USD","LU2324357040.USD","IE00BSNM7G36.USD","LU0096364046.USD","LU1244550577.SGD","LU2471134879.HKD","LU2265009873.SGD","BK4566","IE0002270589.USD","LU2089283258.USD","LU2896262040.SGD","LU2237443549.SGD","IE00BZ1G4Q59.USD","GSX","LU2237438978.USD","IE0034235188.USD","LU1989772840.SGD","KBWB","LU2237443465.HKD","TEVA","LU0314104364.USD","IE0004086264.USD","IE00BKVL7J92.USD","BK4516","BK4533","LU0882574139.USD","LU0345770993.USD","LU1868836757.USD","LU2264538146.SGD","XBI","LU0942090050.USD","LU0210528500.USD","LU1989772923.USD","BK4581","IAI","LU0006306889.USD","LU1791710582.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664587723","title":"AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587723?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:25","pubTimestamp":1788441947,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0203347892.USD","LU1093756325.SGD","LU0320765646.SGD","ABBV","LU0942090050.USD","LU2357627491.SGD","IE00BLSP4239.USD","FHLC","IE000WAW04H5.SGD","BK4550","SG9999011175.SGD","IYH","LU0417517546.SGD","TRUH","LU0912757837.SGD","LU0472753341.HKD","LU0795875169.SGD","GLAM","LU0868494617.USD","LU0057025933.USD","IXJ","MEDX","AGNG","LU1057294990.SGD","LU2089284900.SGD","BK4585","PPH","LU1929549753.HKD","LU1585245621.USD","LU2237443465.HKD","ORR","LU1244550494.USD","LU2129689431.USD","VHT","LU0124676726.USD","LU0882574055.USD","LU0256863811.USD","PJP","JDOC","IE000F7OJYX1.SGD","LU0820561909.HKD","XLV","BK4559","FTXH","LU1496350171.SGD","IE0004445239.USD","LU0965509283.SGD","RXL","LU1989772840.SGD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877895","title":"AbbVie's Blood Cancer Drug Meets Late-Stage Trial Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877895","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877895?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:18","pubTimestamp":1788441527,"startTime":"0","endTime":"0","summary":"AbbVie's blood cancer drug meets late-stage trial goalsSept 3 (Reuters)-AbbVieABBV.Nsaid on Thursday its drug for a type of blood cancer has met the main goals of a late-stage trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4N44V12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLAM","LU0203345920.USD","LU0114720955.EUR","LU0726765562.USD","RXL","ABBV","LU2112291526.USD","LU0820561909.HKD","BK4585","IE000MB6IJN5.SGD","LU0472753341.HKD","PPH","LU1496350171.SGD","IE00BVYPNW00.USD","XLV","IE00BLSP4239.USD","LU0256863902.USD","LU2089283258.USD","LU1585245621.USD","IYH","AGNG","IXJ","LU1934455277.USD","MEDX","PJP","LU1989772923.USD","LU0985320562.USD","SG9999001440.SGD","TRUH","SG9999015945.SGD","JDOC","FTXH","IE00BBT3K403.USD","LU0128525929.USD","LU1934455863.HKD","IE00BN8TJ469.HKD","SG9999015952.SGD","LU0289961442.SGD","LU0942090050.USD","IE0009355771.USD","LU0057025933.USD","LU0211328371.USD","LU0098860793.USD","IE00B3PB1722.GBP","VHT","FHLC","LU0395794307.EUR","IE0004445239.USD","LU2357627491.SGD","LU0820561818.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887207","title":"Abbvie - Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results to be Presented Sept 23-26","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887207?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA9C2QXL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","LU1718418525.SGD","LU0122379950.USD","LU0234572021.USD","LU2087621335.USD","LU0859254822.USD","IE00BBT3K403.USD","FTXH","LU1244550577.SGD","TRUH","IYH","LU2237443549.SGD","LU1291159041.SGD","LU1496350171.SGD","LU0114720955.EUR","PJP","LU2089984988.USD","LU2347655073.USD","LU1244550221.USD","LU1585245621.USD","LU2125909593.SGD","LU1670628061.USD","MEDX","LU1236620834.HKD","LU0965509010.AUD","AGNG","IXJ","LU1983299246.USD","PPH","LU1057294990.SGD","LU2133065610.SGD","LU1093756325.SGD","LU1551013425.SGD","LU1839511570.USD","IE00B4R5TH58.HKD","LU0553294199.USD","LU0511384066.AUD","JDOC","LU0098860793.USD","ABBV","GLAM","FHLC","LU1023059063.AUD","LU0689472784.USD","LU0820561909.HKD","VHT","XLV","RXL","IE00BN8TJ469.HKD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872073","title":"Abbvie - Etentamig Demonstrates Low Rates of Cytokine Release Syndrome and Fatal Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872073?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA9C2QXL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PJP","LU2237443465.HKD","LU0795875169.SGD","LU2089283258.USD","FTXH","IYH","LU1732800096.USD","LU1839511570.USD","LU1934455194.USD","ABBV","SG9999011175.SGD","XLV","LU0234572021.USD","LU2237443382.USD","LU0545039389.USD","SG9999003800.SGD","IXJ","LU1244550494.USD","IE00BBT3K403.USD","BK4588","TRUH","LU0128525929.USD","LU0456855351.SGD","LU1989771016.USD","LU0859254822.USD","LU1244550577.SGD","SG9999001440.SGD","IE00B19Z3B42.SGD","GLAM","LU1430594728.SGD","LU1093756325.SGD","LU2125909593.SGD","PPH","LU0170899867.USD","IE00B3PB1722.GBP","LU1934455863.HKD","MEDX","FHLC","SG9999015945.SGD","IE00B2B36J28.USD","VHT","LU0861579265.USD","LU0943347566.SGD","JDOC","LU0289961442.SGD","RXL","LU0511384066.AUD","LU0942090050.USD","IE000WAW04H5.SGD","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664720768","title":"Abbvie - Etentamig Achieves 74% Orr and 60% Risk Reduction in Phase 3 Cervino Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664720768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664720768?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA9C2QXL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739343.SGD","TRUH","LU2133065610.SGD","PPH","LU0545039389.USD","LU0417517546.SGD","RXL","FHLC","FTXH","LU1934455194.USD","LU0726765562.USD","LU1093756325.SGD","LU0868494708.USD","LU0432979614.USD","LU0965508806.USD","ABBV","LU0170899867.USD","LU2237443382.USD","GLAM","LU1983299246.USD","LU0882574055.USD","IXJ","JDOC","SG9999011175.SGD","BK4588","LU1670628061.USD","VHT","AGNG","LU0861579265.USD","IE000MB6IJN5.SGD","LU1244550577.SGD","LU1934455277.USD","LU0689472784.USD","LU1236620834.HKD","LU1929549753.HKD","XLV","PJP","IE00BJJMRZ35.SGD","LU0859254822.USD","MEDX","BK4533","IE000SO60NU8.SGD","LU1003077747.HKD","LU0795875169.SGD","BK4139","LU0965509283.SGD","IYH","IE000BZT7R73.USD","IE00BJT1NW94.SGD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487207","title":"Abbvie Announces Positive Topline Results from the Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487207?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA9C2QXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0965508806.USD","LU0820561818.USD","LU1244550577.SGD","LU0310800379.SGD","LU2357627491.SGD","LU0417517546.SGD","PPH","IE000F7OJYX1.SGD","LU0432979614.USD","LU0128525929.USD","IE000BZT7R73.USD","LU1923622614.USD","LU0203347892.USD","LU0289961442.SGD","LU1670627923.USD","TRUH","RXL","FTXH","AGNG","LU2129689605.HKD","MEDX","LU1093756325.SGD","VHT","LU0310799852.SGD","ABBV","BK4533","IE0004445239.USD","IE000MB6IJN5.SGD","FHLC","LU1989772923.USD","PJP","IE00B4R5TH58.HKD","LU0198837287.USD","LU1244550221.USD","LU0511384066.AUD","LU0820561909.HKD","GLAM","XLV","LU1934455863.HKD","BK4139","IE0002141913.USD","LU0965509010.AUD","LU2237443622.USD","IE000SO60NU8.SGD","IYH","LU1244550494.USD","LU0456855351.SGD","JDOC","IE00BLSP4452.SGD","IXJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664720938","title":"AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664720938","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664720938?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:13","pubTimestamp":1788441193,"startTime":"0","endTime":"0","summary":"AbbVie  said Thursday that it has completed its acquisition of Apogee Therapeutics , valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.Analysts polled by FactSet expect $3.86 and $14.03, respectively.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","AGNG","LU2237443382.USD","PJP","LU0795875169.SGD","LU0965509101.SGD","LU0432979614.USD","LU2089283258.USD","LU1093756325.SGD","LU0289739343.SGD","IE00BVYPNV92.GBP","JDOC","IE00B19Z3B42.SGD","LU1267930573.SGD","LU1244550494.USD","IXJ","VHT","SBIO","IYH","LU2125909247.SGD","IE00BJJMRZ35.SGD","LU0456855351.SGD","TRUH","ABBV","FHLC","LU0289961442.SGD","LU1061106388.HKD","LU0320765646.SGD","APGE","LU1923622614.USD","LU1023059063.AUD","PPH","LU2237443622.USD","LU0417517546.SGD","LU0310799852.SGD","SG9999011175.SGD","GLAM","LU0738911758.USD","LU0949170772.SGD","LU2129689514.USD","LU0965509010.AUD","RXL","MEDX","LU0057025933.USD","LU0985320562.USD","FTXH","LU0069063385.USD","LU0795875086.SGD","LU1037948897.HKD","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872503","title":"Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872503","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872503?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:54","pubTimestamp":1788440071,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie mergerApogee notified Nasdaq of its merger close, requesting delisting and continued trading halt; shares suspended from trading Sept. 4, 2026.Nasdaq to file SEC Form 25 to delist and deregister the stock under Exchange Act Section 12.Company plans to file SEC Form 15 to terminate registration under Section 12, suspending reporting obligations under Sections 13 and 15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL3D254h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2133065610.SGD","LU2237443549.SGD","LU1670627923.USD","LU2468319806.SGD","PJP","RXL","ABBV","LU0320765646.SGD","LU0943347566.SGD","IE00BN8TJ469.HKD","LU0882574055.USD","VHT","XLV","LU1934455277.USD","LU2237443895.HKD","LU0128525929.USD","LU1061106388.HKD","LU0985320562.USD","IE00BJJMRZ35.SGD","LU2089284900.SGD","IE000MB6IJN5.SGD","LU2129689514.USD","FTXH","SG9999003800.SGD","LU1023059063.AUD","BK4534","JDOC","GLAM","IE00B3PB1722.GBP","APGE","LU2347655073.USD","IE00B19Z3581.USD","SBIO","FHLC","LU0965508806.USD","IXJ","LU1989771016.USD","IE00B4R5TH58.HKD","MEDX","IYH","TRUH","LU0868494708.USD","LU0965509010.AUD","LU2237443382.USD","LU2347655156.SGD","IE000F7OJYX1.SGD","LU2112291526.USD","LU0820561909.HKD","PPH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874741","title":"Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874741","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874741?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:36","pubTimestamp":1788438997,"startTime":"0","endTime":"0","summary":"Aspen sees Mounjaro Africa sales above $124 million in 2027JOHANNESBURG, Sept 3 (Reuters)-Aspen PharmacareAPNJ.Jexpects African sales of Eli Lilly'sLLY.Nblockbuster weight-loss and diabetes drug Mounj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL8N44V0QJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU1623119135.USD","LU2168564495.EUR","LU0106261372.USD","LU0432979614.USD","LU2357305700.SGD","LU1548497426.USD","LU0122379950.USD","SG9999015986.USD","LU2023250504.SGD","SGXZ31699556.SGD","IE00B4JS1V06.HKD","LU0158827948.USD","LU1868837136.USD","LU0006306889.USD","LU1232071149.USD","IE00B775H168.HKD","LU2417539215.USD","IXJ","LU0114720955.EUR","LU2361044949.HKD","LU0133085943.USD","LU2106854487.HKD","SGXZ81514606.USD","TRUH","MHIP","SG9999013999.USD","IE0009355771.USD","IE00B7KXQ091.USD","LU2168563687.JPY","IE00BK4W5M84.HKD","LU0471298694.HKD","IE00B1BXHZ80.USD","LU2111349929.HKD","LU2462591350.SGD","LU0471298777.SGD","LU0823416689.USD","LU2237443549.SGD","LU2324357040.USD","OZEM","LU1983299246.USD","LU0345770308.USD","LU1551013425.SGD","LLII","LU2602419157.SGD","LU2756315318.SGD","ELIS","LU0787776722.HKD","LU1720051108.HKD","LU1988902786.USD","IE00BJJMRY28.SGD","FTXH","IHE","IE00BKDWB100.SGD","IE0004445015.USD","LU2471134952.CNY","LU2168564065.EUR","LU2456880835.USD","TMED","LU2461242641.AUD","LU1814569148.SGD","SGXZ99366536.SGD","LU1093756325.SGD","LU2896262040.SGD","LU2108987350.USD","LU2360106947.USD","BK4533","LU2089284900.SGD","IE00B4R5TH58.HKD","JDOC","LU2756315664.SGD","APNHY","IE0005OL40V9.USD","IE00BJT1NW94.SGD","THNR","BK4585","LU2471134796.USD","LU2746668461.USD","LU1868836591.USD","SG9999014906.USD","IE00BFSS8Q28.SGD","IE0004445239.USD","IYH","LU0158827781.USD","LU0203201768.USD","IE00B1XK9C88.USD","LU0820561909.HKD","BK4534","LU1061106388.HKD","LU0708995401.HKD","LU2271345857.HKD","LU0097036916.USD","LU0109391861.USD","LU1064131342.USD","LU0320765059.SGD","LU0316494557.USD","LU0640476718.USD","LU0964807845.USD","LU0672654240.SGD","LU1057294990.SGD","LU0256863811.USD","LU1366192091.USD","PPH","BK4599","LU2468319806.SGD","IE00BFSS7M15.SGD","LU0320765992.SGD","IE00BJLML261.HKD","SG9999015945.SGD","LU1035775433.USD","LU2237443895.HKD","SG9999014914.USD","LU2213496289.HKD","LU1267930730.SGD","LU1291159041.SGD","LU0882574055.USD","LU0353189763.USD","LU0823434583.USD","SGXZ51526630.SGD","LU0058720904.USD","RXL","LU0094547139.USD","LU1280957306.USD","LU0256863902.USD","LU1145028129.USD","LU2264538146.SGD","WDNA","LU0238689110.USD","LU2552382058.USD","SG9999015952.SGD","XLV","LU0096364046.USD","LU2746668974.SGD","LLYZ","LU1712237335.SGD","LU0266013472.USD","LU2089283258.USD","LU0354030511.USD","IE00B2B36J28.USD","LU0943347566.SGD","LU1093756168.USD","LU1323610961.USD","LU2236285917.USD","LU0225283273.USD","LU2237438978.USD","LU0882574139.USD","LU0683600562.USD","IE00BK4W5L77.USD","BK4007","IE0002141913.USD","LLY","VHT","LU2089984988.USD","IE00BJJMRZ35.SGD","LU0456855351.SGD","IE00BWXC8680.SGD","LU0820561818.USD","LU0323591593.USD","LU2491050154.USD","LU1868837300.USD","LU2462157665.USD","LU2491050071.SGD","LU0417517546.SGD","SG9999018865.SGD","LU1917777945.USD","IE00BFTCPJ56.SGD","SG9999001176.SGD","LU0198837287.USD","ELIL","LU0289739699.SGD","LU0354030438.USD","LU2265009873.SGD","LU2028103732.USD","LU2023251221.USD","LU1691799644.USD","SG9999015978.USD","LU2237443978.SGD","LU0174119429.USD","LU0353189680.USD","LU2750360641.GBP","IE00BKPKM429.USD","MEDI","LU1868836757.USD","BK4588","AGNG","LU1127390331.HKD","LLYX","LU2237443382.USD","LU2750360997.AUD","PJP","SG9999018857.SGD","LU2211815571.USD","ILDR","LU1868836914.USD","LU0689472784.USD","LU2471134523.USD","LU2471134879.HKD","LU0079474960.USD","LU2361045086.USD","GB00BDT5M118.USD","LU0234572021.USD","SG9999017495.SGD","LU2552382132.HKD","LU0210536198.USD","LU2237443465.HKD","SG9999014880.SGD","LU2063271972.USD","CANC","CURE","LU2491049909.HKD","SGXZ57979304.SGD","FHLC","LU0823434740.USD","LU1551013342.USD","LU0889565916.HKD","LU1023059063.AUD","LU2237443622.USD","LU2023250330.USD","LU2087625088.SGD","BK4516","LU1804176565.USD","LU2552382215.SGD","LU0061475181.USD","IE0001KFT4U8.USD","SG9999001176.USD","LU2112291526.USD","SG9999014898.SGD","LU0345770993.USD","IE00BN29S564.USD","LU0466842654.USD","LU1629891620.HKD","HRTS","GDOC","LU1069344957.HKD","LU0786609619.USD","LU1974910355.USD","LU0203202063.USD","LU1979441026.SGD","LU0385154629.USD","LU0820562030.AUD","LU1720051017.SGD","LU1989771016.USD","LU2361044865.SGD","LU2168564222.USD","MEDX","IE00BJJMRX11.SGD","LU0109394709.USD","LU2168564149.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874750","title":"Abbvie Completes Acquisition of Apogee Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874750?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:35","pubTimestamp":1788438900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA5XSP4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2237443465.HKD","PJP","RXL","ABBV","LU2089283258.USD","BK4139","SG9999011175.SGD","LU1496350171.SGD","VHT","IE0002141913.USD","XLV","LU0795875086.SGD","BK4566","LU0912757837.SGD","LU0158827948.USD","SG9999015978.USD","LU0985320562.USD","IE000MB6IJN5.SGD","FTXH","JDOC","IE0004445239.USD","BK4559","GLAM","APGE","LU2087621335.USD","IE00B19Z3581.USD","LU1839511570.USD","SBIO","LU1934455863.HKD","LU0057025933.USD","FHLC","IXJ","LU0511384066.AUD","LU0234570918.USD","LU0820561818.USD","LU1037948541.HKD","LU1291159041.SGD","LU0289739343.SGD","LU2237443978.SGD","MEDX","LU1989772840.SGD","IYH","TRUH","LU0726765562.USD","LU0098860793.USD","IE000F7OJYX1.SGD","LU2112291526.USD","BK4581","PPH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787475","title":"Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787475?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:35","pubTimestamp":1788438900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA5XSP4L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1244550494.USD","MEDX","VHT","LU1718418525.SGD","LU0456855351.SGD","LU2023251221.USD","LU0511384066.AUD","APGE","LU1236620834.HKD","BK4534","LU0234572021.USD","ABBV","FTXH","LU0726765562.USD","LU0128525929.USD","IYH","LU1003077747.HKD","LU1929549753.HKD","LU0098860793.USD","BK4581","LU1983299246.USD","LU2087621335.USD","IE00B3PB1722.GBP","AGNG","GLAM","LU1670627923.USD","SG9999015952.SGD","LU0689626769.HKD","LU0114720955.EUR","LU0053671581.USD","IE00BBT3K403.USD","SBIO","JDOC","FHLC","IXJ","TRUH","LU0965508806.USD","LU1551013342.USD","BK4585","XLV","LU1057294990.SGD","RXL","PJP","LU1934455194.USD","IE00BJJMRZ35.SGD","LU0029864427.USD","LU0965509101.SGD","LU0203347892.USD","PPH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664747838","title":"Press Release: PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2664747838","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664747838?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:30","pubTimestamp":1788438600,"startTime":"0","endTime":"0","summary":"for OcuRing-K, enabling initiation of a multi-center Phase II. clinical trial in the United States in patients undergoing cataract. surgery, with patient enrollment expected in the second half of 2026.-- Reported that PRF-110 demonstrated sustained 72-hour analgesic activity. extended-release benchmark, in a validated porcine post-operative pain. -- Reported expanded results from the same head-to-head study showing slower. systemic absorption, enhanced local tissue retention and sustained. exposure for PRF-110, supporting its development as a. developed as a potential non-opioid option for the management of. -- Entered a commercial collaboration with Blade Ranger to pursue potential. enterprise DeepSolar engagements, each with a minimum scope of 150 MW,-- Strengthened the balance sheet to approximately $11.6 million in cash,short term deposits and cash equivalents as of June 30, 2026, providing. -- Validated DeepSolar Predict using real-world European utility-scale. production, weather","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","LU0029874061.USD","IND","BK4007","PRGS","XBI","LU0128526141.USD","BK4137","BK4581","BK4097","BK4585","BK4555","AIPO","VTHR","03160","BK4232","PRFX","BK4604","PRF","BK4099","R","XLV","HCSG","LABU","FRNW","BK4022","BK4588","TM","AGIX","LU2065732104.USD","QTOC","CHAT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":26,"pageCount":15,"totalSize":518,"code":"91000000","status":"200"}]}}